Endothelial Glycocalyx as a Potential Therapeutic Target in Organ Injuries

0
0
0

Endothelial Glycocalyx as a Potential Therapeutic Target in Organ Injuries

The endothelial glycocalyx (eGC) is a dynamic, multifunctional layer of glycoproteins, proteoglycans, and glycosaminoglycans (GAGs) lining the luminal surface of vascular endothelial cells. This intricate structure plays a critical role in regulating vascular permeability, mechanotransduction, leukocyte adhesion, and coagulation. Emerging evidence highlights its degradation as a key contributor to organ injuries in conditions such as sepsis, ischemia-reperfusion (I/R) injury, diabetes, and atherosclerosis. This review explores the pathophysiological implications of eGC damage and evaluates therapeutic strategies to preserve or restore its integrity.

Structural Composition of the Endothelial Glycocalyx

The eGC consists of heparan sulfate (HS, 50–90% of total GAGs), hyaluronic acid (HA), and chondroitin/dermatan sulfate (CS). These components are anchored to core proteins such as syndecans, glypicans, and CD44, forming a dense matrix interwoven with plasma proteins like albumin and orosomucoid. The endothelial surface layer (ESL), a thicker structure encompassing the eGC and adsorbed plasma components, serves as a dynamic barrier against circulating cells and macromolecules. Structural variations exist across organs; for example, the glomerular endothelial glycocalyx is fenestrated, while cerebral capillaries exhibit a continuous layer integral to the blood-brain barrier.

Physiological Functions of the Glycocalyx

  1. Regulation of Vascular Permeability
    The eGC acts as a primary barrier, limiting fluid and protein extravasation. Enzymatic removal of HS or HA increases vascular permeability by 50–90%, demonstrating its role in maintaining oncotic and hydrostatic pressure gradients. In the glomerulus, eGC degradation precedes podocyte injury and proteinuria. For instance, 15 minutes of renal I/R reduces glomerular charge selectivity, leading to albuminuria without structural podocyte damage.

  2. Mechanotransduction and Nitric Oxide Production
    Shear stress activates eGC-bound GAGs, triggering calcium influx via transient receptor potential (TRP) channels and nitric oxide (NO) synthesis. This pathway is critical for vasodilation and vascular homeostasis. Disruption of HS or HA impairs NO release, exacerbating endothelial dysfunction.

  3. Modulation of Inflammation and Coagulation
    The eGC prevents leukocyte and platelet adhesion by masking adhesion molecules like ICAM-1 and P-selectin. In sepsis, glycocalyx shedding exposes these receptors, promoting neutrophil infiltration and microthrombosis. Matrix metalloproteinase-7 (MMP7)-mediated syndecan-1 cleavage increases platelet adherence by 40% in human umbilical vein endothelial cells (HUVECs).

Pathological Conditions Associated with Glycocalyx Degradation

  1. Sepsis and Trauma
    Circulating syndecan-1 and heparan sulfate levels rise 10–65-fold in septic patients, correlating with mortality. Tumor necrosis factor-α (TNF-α) activates heparanase, cleaving HS and disrupting the pulmonary endothelial barrier within 30 minutes. Trauma patients with elevated syndecan-1 (>16.5 ng/mL) exhibit higher rates of coagulopathy and mortality.

  2. Ischemia-Reperfusion Injury
    In guinea pig hearts, 20 minutes of ischemia degrades the eGC, increasing coronary perfusion pressure by 30% and histamine release. Renal I/R in mice upregulates heparanase, exacerbating inflammation and fibrosis. Post-cardiopulmonary bypass, plasma syndecan-1 increases 42-fold, reflecting systemic glycocalyx damage.

  3. Hypervolemia and Hypertension
    Atrial natriuretic peptide (ANP) released during hypervolemia induces eGC shedding, elevating transudate formation by 25%. Chronic hypertension reduces cerebral capillary glycocalyx thickness by 50%, disrupting the blood-brain barrier.

  4. Diabetes and Hyperglycemia
    Acute hyperglycemia (blood glucose >200 mg/dL) reduces sublingual glycocalyx volume by 20%, impairing microcirculatory perfusion. In diabetic nephropathy, endothelin-1 upregulates heparanase in podocytes, degrading glomerular eGC and increasing albuminuria 3-fold.

  5. Atherosclerosis
    Oxidized LDL binds to HS, promoting leukocyte adhesion and plaque formation. ApoE knockout mice with thin eGC exhibit 50% higher macrophage recruitment and thrombotic events.

Detection Methods and Clinical Biomarkers

  1. Imaging Techniques

    • Electron Microscopy: Lanthanum staining reveals eGC thickness (30–200 nm) in renal and pulmonary capillaries.
    • Sidestream Dark-Field Imaging: Measures sublingual perfused boundary region (PBR). Dialysis patients show PBR values of 3.3 µm (vs. 2.1 µm in healthy controls), indicating glycocalyx damage.
    • Intravital Microscopy: FITC-dextran exclusion assays quantify eGC thickness (1.5 µm in healthy vs. 0.5 µm in septic mice).

  2. Circulating Biomarkers

    • Plasma syndecan-1 >90 ng/mL predicts mortality in sepsis.
    • Urinary glycosaminoglycan fragments correlate with acute kidney injury in septic shock (AUC = 0.82).

Therapeutic Strategies for Glycocalyx Protection and Restoration

  1. Fluid Management
    Fresh frozen plasma (FFP) resuscitation preserves eGC thickness by 60% compared to crystalloids in hemorrhagic shock. Albumin, but not hydroxyethyl starch, prevents interstitial edema in ischemic hearts by maintaining glycocalyx integrity.

  2. Pharmacological Interventions

    • Anticoagulants: Unfractionated heparin reduces sepsis-induced syndecan-1 shedding by 30%. Non-anticoagulant heparinoids inhibit leukocyte adhesion via HS domain blockade.
    • Glucocorticoids: Hydrocortisone (5 mg/kg) attenuates TNF-α-induced eGC degradation and reduces post-I/R neutrophil adhesion by 50%.
    • Sphingosine-1-Phosphate (S1P): Activates S1P1 receptors, inhibiting MMP7 and restoring syndecan-1 expression, reducing platelet adhesion by 40%.

  3. Enzyme Inhibition

    • Heparanase Inhibitors: PG545 reduces renal fibrosis by 70% in I/R models.
    • MMP Inhibitors: Batimastat prevents TNF-α-mediated syndecan-4 shedding in glomerular endothelial cells.

  4. Glycocalyx Component Supplementation
    Exogenous HS and HA restore endothelial barrier function in vitro. Sulodexide (a GAG mixture) increases retinal glycocalyx thickness by 15% in diabetic patients, lowering albuminuria by 25%.

  5. Nanomaterials and Biomimetics
    Heparin-coated nanoparticles reduce thrombogenicity by 80% in experimental models. Corline heparin conjugate mimics proteoglycans, improving transplant organ viability.

  6. Chinese Herbal Derivatives
    Neferine and berberine inhibit ROS and MMP9, reducing eGC degradation in sepsis by 50%.

Conclusion

The endothelial glycocalyx is a pivotal regulator of vascular homeostasis, with its degradation serving as an early biomarker and therapeutic target in diverse pathologies. Preclinical studies demonstrate that glycocalyx preservation improves microcirculatory perfusion, reduces inflammation, and mitigates organ injury. Clinical translation of strategies like targeted enzyme inhibition, heparanase blockers, and S1P analogs holds promise for improving outcomes in sepsis, diabetes, and cardiovascular diseases. Future research should focus on optimizing glycocalyx-targeted therapies through large-scale trials and advanced imaging modalities.

doi.org/10.1097/CM9.0000000000000177

Was this helpful?

0 / 0